Opinion
Video
TAR-200 Clinical Development Program in NMIBC
Author(s):
Experts briefly mention other ongoing phase 3 studies investigating TAR-200 for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Video Player is loading.
Video content above is prompted by the following:
- Can you briefly mention other ongoing phase 3 studies with TAR-200?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
The ADVANCED-2 trial, TARA-002
Unmet needs in high risk NMIBC
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
The Current Landscape of ADT in Prostate Cancer
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Related Content
